Long-term survival of dialysis patients after coronary bypass grafting

Dacey, Lawrence J.; Liu, Jean Y.; Braxton, John H.; Weintraub, Ronald M.; DeSimone, Joseph; Charlesworth, D.; Lahey, Stephen J.; Ross, Cathy S.; Hernandez, Felix; Leavitt, Bruce J.; O’Connor, Gerald T.

doi:10.1016/s0003-4975(02)03768-2

Cited by 72 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many reports indicate that OPCAB is better than on-pump CABG in terms of early results, but there is no difference in long-term results. 3,[16][17][18] Shroff, et al found in a survey of 13,085 patients on dialysis in the USRDS database that estimated all-cause survival rates were significantly higher for OPCAB at 30 days postoperatively, but no differences were reported between OPCAB and on-pump CABG after 6 months, and 1, 2 and 3 years. 18) Past reports have all been on surveys from various databases or retrospective studies in single-center.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Results of Dialysis Patients with Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting

Sezai

Nakata

Hata

et al. 2013

ATCS

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Long-Term Results of Dialysis Patients with Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting

Sezai

Nakata

Hata

et al. 2013

ATCS

View full text Add to dashboard Cite

“…The 5-year survival rate in dialysis patients after myocardial infarction is reported to be 10%, 5 but Nakayama et al reported a superior survival rate (93% at 8 years) after multi-arterial revascularization. 12 The reported 5-year survival rate of surgically revascularized dialysis patients ranges from 32% 6 to 55.8%, 7 but if there are associated diseases, such as DM or ASO, the rate drops to between 22.9% 13 and 42.2%. 7 The poor long-term results are considered to be related the combination of other diseases, such as cerebrovascular disease 14 and ASO, and also due to the difficulty of complete revascularization 15 because of calcified arteries and the rapid progress of new coronary lesions.…”

Section: Discussionmentioning

confidence: 99%

“…12 The reported 5-year survival rate of surgically revascularized dialysis patients ranges from 32% 6 to 55.8%, 7 but if there are associated diseases, such as DM or ASO, the rate drops to between 22.9% 13 and 42.2%. 7 The poor long-term results are considered to be related the combination of other diseases, such as cerebrovascular disease 14 and ASO, and also due to the difficulty of complete revascularization 15 because of calcified arteries and the rapid progress of new coronary lesions. Generally, the long-term result of using the interval thoracic artery (ITA) is much better than for a vein graft, 16 and there are reports of the advantage of multi-arterial grafts compared with the single ITA and additional SVGs.…”

Section: Discussionmentioning

confidence: 99%

Does Myocardial Revascularization With Multiple Arterial Grafts Improve the Prognosis of Dialysis Patients?

Tanaka

Narisawa

Mori

et al. 2003

Circ J

View full text Add to dashboard Cite

“…The Northern New England Cardiovascular Disease Study analyzed clinical outcomes of 279 dialysis patients and 15,271 patients who had normal renal function and were undergoing CABG (31,32). The patients with ESRD were older and had significantly more comorbid conditions, including diabetes, peripheral vascular disease, and chronic obstructive pulmonary disease.…”

Section: Coronary Revascularization In Esrdmentioning

confidence: 99%

“…Patients with ESRD were 4.4 times more likely to experience in-hospital mortality than were the other CABG patients (odds ratio 4.4; 95% confidence interval 3.0 to 6.4; P Ͻ 0.001), a three-fold higher risk for mediastinitis, and a two-fold higher risk for stroke compared with patients who were undergoing CABG and were not on dialysis. Another study from the same database reported 5-yr survival after CABG as 83.5% for patients with normal renal function and 55.8% for all patients with ESRD (32). Data on coronary revascularization from the United States Renal Data System database have been reported in 14,306 dialysis patients who underwent their first coronary revascularization procedure after initiation of dialysis (33).…”

Section: Coronary Revascularization In Esrdmentioning

confidence: 99%

Coronary Artery Disease

McCullough

2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Coronary heart disease is the most common cause of death in the general population and in patients with ESRD. The principles of cardiovascular risk assessment and management apply to both populations. Advances in noninvasive coronary artery imaging have improved early detection of subclinical disease. The goals of medical management of coronary disease are to modify the natural history of disease and to improve the symptoms of angina. Coronary revascularization poses a different risk and benefit equation in the ESRD population. In stable ESRD with multivessel coronary artery disease, coronary bypass surgery, despite the upfront risks of stroke, myocardial infarction, and chest wound infection, seems to be a favored approach. In patients with ESRD and acute coronary syndromes, percutaneous coronary intervention on the target vessel has been associated with the most favorable outcomes. This article explores the clinical issues with respect to coronary artery disease in patients with ESRD.Clin J Am Soc Nephrol 2: 611-616, 2007611-616, . doi: 10.2215 C oronary heart disease is the leading cause of death in the US general population. With the obesity pandemic and the expected worsening of cardiovascular risk factors in the general population, the incidence and the prevalence of heart disease is expected to rise. Coronary artery disease (CAD) is the leading cause of death in patients with chronic kidney disease (CKD): Of the more than 320,000 patients with ESRD that requires dialysis or kidney transplantation in the United States, half will die from cardiovascular causes, and patients with milder degrees of CKD are more likely to die of CAD than to develop kidney failure that requires renal replacement therapy (1).The observational studies concerning CAD and ESRD have revealed the following: (1) By the time patients reach dialysis, approximately 70% have significant coronary artery calcification indicative of coronary atherosclerosis, (2) patients with CAD and ESRD have markedly increased mortality over the general population, (3) treatment with disease-modifying therapy that is proved to reduce rates of (MI) or death (e.g., aspirin, ␤ adrenergic receptor blockers [BB], angiotensin-converting enzyme inhibitors [ACEI], 3-methylglutaryl CoA reductase inhibitors or statins) are used less frequently in patients with ESRD than in the general population, (4) noninvasive imaging seems to have less precision and accuracy in patients with ESRD, and (5) patients who have ESRD and are selected for revascularization with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) have improved survival compared with those who are treated with medical therapy alone (2-6). Table 1 presents a summary of CAD risk reduction, diagnosis, and management principles. Recommendations in Table 1 present a task list for optimal (not minimal) clinical goals and go beyond many current professional society guidelines concerning the individual treatment targets. ESRD: More Than a Coronary Heart Risk EquivalentPatients with ES...

show abstract

Long-term survival of dialysis patients after coronary bypass grafting

Cited by 72 publications

References 20 publications

Long-Term Results of Dialysis Patients with Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting

Long-Term Results of Dialysis Patients with Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting

Does Myocardial Revascularization With Multiple Arterial Grafts Improve the Prognosis of Dialysis Patients?

Coronary Artery Disease

Contact Info

Product

Resources

About